Objective To evaluate changes of nuclear factor-kappa B (NF-κB) during radioiodine 131 (131I) therapy and whether NF-κB inhibition could enhance 131I-induced apoptosis in differentiated thyroid cancer (DTC) cells in a synergistic manner. Methods Three human DTC cell lines were used. NF-κB inhibition was achieved by using a NF-κB inhibitor (Bay 11-7082) or by p65 siRNA transfection. Methyl-thiazolyl-tetrazolium assay was performed for cell viability assessment. DNA-binding assay, luciferase reporter assay, and Western blot were adopted to determine function and expression changes of NF-κB. Then NF-κB regulated anti-apoptotic factors XIAP, cIAP1, and Bcl-xL were measured. Apoptosis was analyzed by Western blot for caspase 3 and PARP, and by flow cytometry as well. An iodide uptake assay was performed to determine whether NF-κB inhibition could influence radioactive iodide uptake. Results The methyl-thiazolyl-tetrazolium assay showed significant decrease of viable cells by combination therapy than by mono-therapies. The DNA-binding assay and luciferase reporter assay showed enhanced NF-κB function and reporter gene activities due to 131I, yet significant suppression was achieved by NF-κB inhibition. Western blot proved 131I could increase nuclear NF-κB concentration, while NF-κB inhibition reduced NF-κB concentration. Western blot also demonstrated significant up-regulation of XIAP, cIAP1, and Bcl-xL after 131I therapy. And inhibition of NF-κB could significantly down-regulate these factors. Finally, synergism induced by combined therapy was displayed by significant enhancements of cleaved caspase 3 and PARP from Western blot, and of Annexin V positively staining from flow cytometry. The iodine uptake assay did not show significant changes when NF-κB was inhibited. Conclusion We demonstrated that 131I could induce NF-κB activation, which would attenuate 131I efficacy in DTC cells. NF-κB inhibition by Bay 11-7082 or by p65 siRNA transfection was effective in suppressing NF-κB regulated anti-apoptotic changes and in combined regimen apoptosis was achieved synergistically.
References
[1]
Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295: 2164–2167.
[2]
Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, et al. (2006) Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91: 313–319.
[3]
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, et al. (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892–2899.
[4]
Pfister DG, Fagin JA (2008) Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol 26: 4701–4704.
[5]
Tan J, Zhang G, Xu W, Meng Z, Dong F, et al. (2009) Thyrotoxicosis due to functioning metastatic follicular thyroid carcinoma after twelve I-131 therapies. Clin Nucl Med 34: 615–619.
[6]
O'Neill CJ, Oucharek J, Learoyd D, Sidhu SB (2010) Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 15: 146–156.
[7]
Pacifico F, Leonardi A (2010) Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321: 29–35.
[8]
Namba H, Saenko V, Yamashita S (2007) Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metabol 51: 843–851.
[9]
Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, et al. (2008) Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 149: 5357–5365.
[10]
Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S (2004) Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 89: 410–418.
[11]
Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, et al. (2004) Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 10: 6821–6829.
[12]
Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, et al. (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91: 4013–4021.
[13]
Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, et al. (2006) BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147: 5699–5707.
[14]
Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431–436.
[15]
Duan J, Friedman J, Nottingham L, Chen Z, Ara G, et al. (2007) Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6: 37–50.
[16]
Wu X, Zhu Y, Yan H, Liu B, Li Y, et al. (2010) Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells. BMC Cancer 10: 269.
[17]
Weiss SJ, Philp NJ, Grollman EF (1984) Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114: 1090–1098.
[18]
Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33–40.
[19]
Woyach JA, Shah MH (2009) New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 16: 715–731.
Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, et al. (2004) Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279: 54610–54619.
[22]
Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, et al. (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15: 1987–1994.
[23]
Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR (2004) Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 10: 3333–3341.
[24]
Wang C, Sheng G, Lu J, Xie L, Bai S, et al. (2012) Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo. Mol Cell Biochem 359: 125–133.
[25]
Wu W, Yao D, Wang Y, Qiu L, Sai W, et al. (2010) Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumour Biol 31: 605–611.
[26]
Kucharczak J, Simmons MJ, Fan Y, Gelinas C (2003) To be, or not to be: NF-kappaB is the answer–role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961–8982.
[27]
Marx K, Moka D, Schomacker K, Fischer T, Gabruk-Szostak B, et al. (2006) Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis? Nucl Med Commun 27: 353–358.
